(Q50939956)

English

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.

scientific article published in July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Wenhui Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Walter J J Krauwinkel

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

James Keirns

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Robert W Townsend

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Kenneth C Lasseter

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Lisa Plumb

6

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Takeshi Kadokura

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Fumihiko Ushigome

8

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Ronald Smulders

9

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Clinical Drug Investigation

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

33

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

7

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

489-496

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0089-6

21 January 2018

Localization of uridine 5'-diphosphate-glucuronosyltransferase in human liver injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733389

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733389

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Renal Na(+)-glucose cotransporters

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733389

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UDP glucuronosyltransferase mRNA levels in human liver disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23733389

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40261-013-0089-6

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/23733389

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50939956&oldid=2143887461"